OCMS BIO LLC

Wynnewood, PA · Biotech · Private

On-cell monoclonal antibody (OCMS) screening platform using an anchor-linker system to enable rapid cell-based antibody discovery and characterization

Claim this profile

Follows are private to you and power your alerts

Updated · ocms.bio

Sector
Biotech
Headquarters
Wynnewood, PA
Total capital
$700K
Federal grants
$700K
2 awards · 2023
Rank in peer group#37 of 48
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
2 pending

Capital timeline

2023FEDERAL ↑EQUITY ↓Cumulative $700K$350K$350K
2023FEDERAL ↑EQUITY ↓Cumulative $700K$350K$350K

Latest events

  • Federal grantHealth and Human S · Phase I · On-cell screening of mouse hybridomas for improved monoclonal antibody discovery$350K
  • Federal grantHealth and Human S · Phase I · On-cell screening of mouse hybridomas for improved monoclonal antibody discovery$350K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 48 peers

Line = median

Biotech · Platform

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 2
  • PendingRsv-targeting AntibodiesUSPTOApplication PCTUS2025048310
  • PendingRsv-targeting AntibodiesUSPTOApplication 63700421

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .